

**bs-20428R****[ Primary Antibody ]****VWF Rabbit pAb****BioSS**  
**ANTIBODIES**

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

**— DATASHEET —**

<b>Host:</b> Rabbit <b>Clonality:</b> Polyclonal <b>GeneID:</b> 7450 <b>Target:</b> VWF <b>Immunogen:</b> KLH conjugated synthetic peptide derived from human VWF: 1701-1800/2813. <b>Purification:</b> affinity purified by Protein A <b>Concentration:</b> 1mg/ml <b>Storage:</b> Preservative: 0.02% Proclin300, Constituents: 1% BSA, 0.01M PBS, pH7.4. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. <b>Background:</b> Von Willebrand Factor (VWF) was previously known as Factor VIII related antigen. VWF is synthesized exclusively by endothelial cells and megakaryocytes, and stored in the intracellular granules or constitutively secreted into plasma. This glycoprotein functions as both an antihemophilic factor carrier and a platelet vessel wall mediator in the blood coagulation system. Important in the maintenance of homeostasis, it participates in platelet vessel wall interactions by forming a noncovalent complex with coagulation factor VIII at the site of vascular injury. The Von Willebrand factor has functional binding domains to platelet glycoprotein Ib, glycoprotein IIb/IIIa, collagen and heparin. Mutations in this gene or deficiencies in this protein result in Von Willebrand's disease. VWD is characterized by frequent bleeding (gingival, minor skin quantitative lacerations, menorrhagia, etc.).	<b>Isotype:</b> IgG <b>SWISS:</b> P04275 <b>Applications:</b> Flow-Cyt (3ug/Test) <b>Reactivity:</b> Human (predicted: Mouse, Rat, Rabbit, Pig, Dog) <b>Predicted MW.:</b> 226/309 kDa <b>Subcellular Location:</b> Secreted ,Extracellular matrix
---	---

**— VALIDATION IMAGES —**

Blank control (Black line):HUVEC(Black). Primary Antibody (green line): Rabbit Anti-VWF antibody (bs-20428R) Dilution: 3µg /10<sup>6</sup> cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody (white blue line): Goat anti-rabbit IgG-PE Dilution: 1µg /test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with PBST for 20 min at room temperature. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

**— SELECTED CITATIONS —**

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

- **[IF=11.322]** Yonghong Fan. et al. Construction of tissue-engineered vascular grafts with high patency by mimicking immune stealth and blocking TGF- $\beta$  mediated endothelial-to-mesenchymal transition. COMPOS PART B-ENG. 2023 Feb;251:110487 IF ;Human. 10.1016/j.compositesb.2022.110487
- **[IF=10.2]** Fei Sun. et al. In Situ Vascularization and Epithelialization of Segmental Bioengineered Trachea Based on Marrow-Derived Stem/Progenitor Cells. MATER TODAY BIO. 2025 Jun;;101990 IF ;Rabbit. 40605986
- **[IF=7.2]** Lin Niu. et al. Magnolol alleviates pulmonary fibrosis in chronic obstructive pulmonary disease by targeting transient receptor potential vanilloid 4-ankyrin repeat domain. PHYTOTHER RES. 2023 Jun;; IF ;Mouse. 37282760
- **[IF=5.88]** Fei Sun. et al. Directly construct microvascularization of tissue engineering trachea in orthotopic transplantation. Mat Sci Eng C-Mater. 2021 May;;112201 IF ;Rabbit. 10.1016/j.msec.2021.112201
- **[IF=0]** Li J et al. Cilostazol Promotes Angiogenesis and Increases Cell Proliferation After Myocardial Ischemia–Reperfusion Injury Through a cAMP-Dependent Mechanism. Cardiovasc Eng Technol. 2019 Oct 17. IHC ;Rat. 31625080